214 related articles for article (PubMed ID: 35543859)
1. Expression of NOTCH1, NOTCH4, HLA-DMA and HLA-DRA is synergistically associated with T cell exclusion, immune checkpoint blockade efficacy and recurrence risk in ER-negative breast cancer.
Liu D; Hofman P
Cell Oncol (Dordr); 2022 Jun; 45(3):463-477. PubMed ID: 35543859
[TBL] [Abstract][Full Text] [Related]
2. Association of Notch pathway down-regulation with Triple Negative/Basal-like breast carcinomas and high tumor-infiltrating FOXP3+ Tregs.
Ortiz-Martínez F; Gutiérrez-Aviñó FJ; Sanmartín E; Pomares-Navarro E; Villalba-Riquelme C; García-Martínez A; Lerma E; Peiró G
Exp Mol Pathol; 2016 Jun; 100(3):460-8. PubMed ID: 27118257
[TBL] [Abstract][Full Text] [Related]
3. Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.
Liu D
Breast Cancer Res Treat; 2020 Aug; 183(1):95-105. PubMed ID: 32601968
[TBL] [Abstract][Full Text] [Related]
4. NILCO biomarkers in breast cancer from Chinese patients.
Colbert LS; Wilson K; Kim S; Liu Y; Oprea-Ilies G; Gillespie C; Dickson T; Newman G; Gonzalez-Perez RR
BMC Cancer; 2014 Apr; 14():249. PubMed ID: 24716804
[TBL] [Abstract][Full Text] [Related]
5. HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC.
Mei J; Jiang G; Chen Y; Xu Y; Wan Y; Chen R; Liu F; Mao W; Zheng M; Xu J
BMC Cancer; 2022 Jul; 22(1):738. PubMed ID: 35794593
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
7. A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer.
Piao XM; Kang HW; Jeong P; Byun YJ; Lee HY; Kim K; Seo SP; Kim WT; Lee JY; Ha YS; Choi YH; Moon SK; Yun SJ; Kim WJ
Urol Oncol; 2021 Apr; 39(4):237.e21-237.e29. PubMed ID: 33339725
[TBL] [Abstract][Full Text] [Related]
8. Notch1 and Notch4 are markers for poor prognosis of hepatocellular carcinoma.
Ahn S; Hyeon J; Park CK
Hepatobiliary Pancreat Dis Int; 2013 Jun; 12(3):286-94. PubMed ID: 23742774
[TBL] [Abstract][Full Text] [Related]
9. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
Front Immunol; 2021; 12():749459. PubMed ID: 34603338
[TBL] [Abstract][Full Text] [Related]
10. An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.
Yau C; Sninsky J; Kwok S; Wang A; Degnim A; Ingle JN; Gillett C; Tutt A; Waldman F; Moore D; Esserman L; Benz CC
Breast Cancer Res; 2013; 15(5):R103. PubMed ID: 24172169
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of miR-1179 inhibits breast cancer cell metastasis by modulating Notch signaling pathway and correlates with favorable prognosis.
Li WJ; Xie XX; Bai J; Wang C; Zhao L; Jiang DQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8374-8382. PubMed ID: 30556878
[TBL] [Abstract][Full Text] [Related]
12. BTN3A2 serves as a prognostic marker and favors immune infiltration in triple-negative breast cancer.
Cai P; Lu Z; Wu J; Qin X; Wang Z; Zhang Z; Zheng L; Zhao J
J Cell Biochem; 2020 Mar; 121(3):2643-2654. PubMed ID: 31692043
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor-positive breast cancer.
Egelston CA; Guo W; Tan J; Avalos C; Simons DL; Lim MH; Huang YJ; Nelson MS; Chowdhury A; Schmolze DB; Yim JH; Kruper L; Melstrom L; Margolin K; Mortimer JE; Yuan Y; Waisman JR; Lee PP
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 35132960
[TBL] [Abstract][Full Text] [Related]
14. Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer.
Jang BS; Han W; Kim IA
Radiother Oncol; 2020 Jan; 142():202-209. PubMed ID: 31767471
[TBL] [Abstract][Full Text] [Related]
15. NOTCH Single Nucleotide Polymorphisms in the Predisposition of Breast and Colorectal Cancers in Saudi Patients.
Alanazi IO; Shaik JP; Parine NR; Al Naeem A; Azzam NA; Almadi MA; Aljebreen AM; Alharbi O; Alanazi MS; Khan Z
Pathol Oncol Res; 2021; 27():616204. PubMed ID: 34257585
[TBL] [Abstract][Full Text] [Related]
16. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer.
Zhou L; Wang D; Sheng D; Xu J; Chen W; Qin Y; Du R; Yang X; He X; Xie N; Liu S; Zhang L
Theranostics; 2020; 10(5):2405-2421. PubMed ID: 32104513
[No Abstract] [Full Text] [Related]
17. Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers.
Yi J; Ren L; Li D; Wu J; Li W; Du G; Wang J
Biomed Pharmacother; 2020 Apr; 124():109827. PubMed ID: 31986408
[TBL] [Abstract][Full Text] [Related]
18. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
19. Screening potential immune signatures for early-stage basal-like/triple-negative breast cancer.
Wu M; Yuan K; Lyu S; Li Y
World J Surg Oncol; 2022 Jun; 20(1):214. PubMed ID: 35751103
[TBL] [Abstract][Full Text] [Related]
20. A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors.
Pérez-Pena J; Tibor Fekete J; Páez R; Baliu-Piqué M; García-Saenz JÁ; García-Barberán V; Manzano A; Pérez-Segura P; Esparis-Ogando A; Pandiella A; Gyorffy B; Ocana A
Front Immunol; 2019; 10():2802. PubMed ID: 31921107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
